MNPR - Monopar Therapeutics Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 12.43M
Enterprise value 752.50k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.38
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.07

Trading information

Stock price history

Beta (5Y monthly) 0.99
52-week change 3-59.08%
S&P500 52-week change 314.65%
52-week high 34.8800
52-week low 30.8110
50-day moving average 31.0795
200-day moving average 32.1649

Share statistics

Avg vol (3-month) 3282.28k
Avg vol (10-day) 31.6M
Shares outstanding 513.22M
Implied shares outstanding 6N/A
Float 84.92M
% held by insiders 162.59%
% held by institutions 11.42%
Shares short (14 May 2023) 479.06k
Short ratio (14 May 2023) 44.5
Short % of float (14 May 2023) 41.66%
Short % of shares outstanding (14 May 2023) 40.60%
Shares short (prior month 13 Apr 2023) 462.38k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-44.34%
Return on equity (ttm)-80.99%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-10.49M
Diluted EPS (ttm)-0.8300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)11.68M
Total cash per share (mrq)0.88
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.08
Book value per share (mrq)0.68

Cash flow statement

Operating cash flow (ttm)-7.03M
Levered free cash flow (ttm)-3.11M